The Globe and Mail reports in its Wednesday, Feb. 12, edition that National Bank Financial analyst Cameron Doerksen has reaffirmed his "sector perform" recommendation for Andlauer Healthcare Group. The Globe's David Leeder writes that Mr. Doerksen jacked his share target up to $49 from $45. Analysts on average target the shares at $48.67. Mr. Doerksen says in a note: "We remain positive on Andlauer Healthcare Group's market positioning in Canada and the secular growth outlook for the company which remains positive for 2025. With low leverage and solid free cash flow, the company is also well positioned for M&A, and we expect the company could be more active in 2025. Our neutral stance on the stock is primarily driven by valuation, which we still consider to be relatively fair." The Globe reported on March 8 that Mr. Doerksen had reaffirmed his "sector perform" recommendation for Andlauer. The shares were then going for $42.70. The Globe reported on Nov. 8 that TD Cowen analyst Tim James continued to rank Andlauer "buy." The shares could then be had for $43. The Globe reported on Feb. 4 that RBC analyst Walter Spracklin had reaffirmed his "sector perform" call for Andlauer, which was then worth $46.30.